When you envision FIS, you will see a reliable, long-term partner with an integrated contract manufacturing organization able to manage small-molecule APIs and Intermediates projects from Development to Commercial production.
With our quality management system, R&D capabilities, and production technology platform, FIS represents your partner of choice for building a solid business relationship.
Development & Manufacturing
Contract Develop. & Manufact.
for Veterinary business
Services for Sterilization, Micronization, Lyophilization, Spray Drying
FIS is authorized by the Italian Medicines Agency (AIFA) and the Italian Ministry of Health to produce more than 100 APIs of various therapeutic classes, for anticancer treatments, steroids, psychotropics and non-beta lactam antibiotics, as well as APIs for veterinary use. Production takes place in dedicated or segregated plants or on multi-purpose lines, depending on product category. FIS’ Montecchio facility was also authorized in 2016 to produce semi-finished pharmaceutical product batches with Spray Dry technology.
Our excellence and growth go hand in hand with those of our employees; people who are encouraged to express their full potential across all roles and responsibilities. Today, we are a company of over 1,750 highly specialized personnel carrying out innovative and challenging projects every day: 250 involved in research and development, 420 graduates, 320 scientists, 70 engineers, of which 50 chemical engineers.
Download our Sustainability Report, prepared in accordance with international Global Reporting Initiative G4 guidelines, which gives a 360-degree account of our company’s operations, beyond the numbers and economic performance that are simply not enough to tell the whole story of our world. Sustainability is a guiding principle in our activities, and fundamental for our contribution to sustainable development to the benefit of the company, its employees and the local community.
FIS is part of the Nine Trees Group, a holding of the Ferrari Family, also including Delmar (CA), FIS North America (USA), PHF (CH), China Office (RPC) and Anemocyte (IT). The core business of the Group companies is the production of active and intermediate ingredients for the global pharmaceutical industry. The different companies share consolidated and consistently practiced values, such as agility, stability, discretion, closeness to local communities and a responsible entrepreneurial vision, today and for the future.